Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 995
Single User License Price INR 69650
Corporate User License Price USD 2985
Corporate User License Price INR 208950
Site License Price USD 1990
Site License Price INR 139300
Request a Quote

Report Title

Generics BRIC (Brazil, Russia, India, China) Industry Guide_2017

Quote Request for License Type
License Type Price  
Single User License USD 995
Site License USD 1990
Enterprise Wide License USD 2985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Generics BRIC (Brazil, Russia, India, China) Industry Guide_2017


Quote Request for License Type
License Type Price  
Single User License USD 995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Generics BRIC (Brazil, Russia, India, China) Industry Guide_2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Generics BRIC (Brazil, Russia, India, China) Industry Guide_2017



Executive Summary

Generics BRIC (Brazil, Russia, India, China) Industry Guide_2017

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $87.2 billion in 2016. China was the fastest growing country with a CAGR of 15.5% over the 2012-16 period.

Within the generics industry, China is the leading country among the BRIC nations with market revenues of $63.1 billion in 2016. This was followed by India, Russia and Brazil with a value of $13.3, $7.0, and $3.9 billion, respectively.

China is expected to lead the generics industry in the BRIC nations with a value of $104.9 billion in 2021, followed by India, Russia, Brazil with expected values of $25.8, $9.6 and $4.1 billion, respectively.

Scope

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the BRIC generics market

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market

Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume

Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to buy

What was the size of the BRIC generics market by value in 2016?

What will be the size of the BRIC generics market in 2021?

What factors are affecting the strength of competition in the BRIC generics market?

How has the market performed over the last five years?

Who are the top competitors in the BRIC generics market?

Table of Contents

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

BRIC Generics

Industry Outlook

Generics in Brazil

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in China

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in India

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Russia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading companies

Appendix

Methodology

About MarketLine

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Figure 1: BRIC generics industry, revenue($bn), 2012-21

Figure 2: BRIC generics industry, revenue($bn), 2012-16

Figure 3: BRIC generics industry, revenue($bn), 2016-21

Figure 4: Brazil generics market value: $ billion, 2012-16

Figure 5: Brazil generics market volume: % of total pharma volume, 2012-16

Figure 6: Brazil generics market geography segmentation: % share, by value, 2016

Figure 7: Brazil generics market value forecast: $ billion, 2016-21

Figure 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Figure 9: Forces driving competition in the generics market in Brazil, 2016

Figure 10: Drivers of buyer power in the generics market in Brazil, 2016

Figure 11: Drivers of supplier power in the generics market in Brazil, 2016

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016

Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2016

Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2016

Figure 15: China generics market value: $ billion, 2012-16

Figure 16: China generics market volume: % of total pharma volume, 2012-16

Figure 17: China generics market geography segmentation: % share, by value, 2016

Figure 18: China generics market value forecast: $ billion, 2016-21

Figure 19: China generics market volume forecast: % of total pharma volume, 2016-21

Figure 20: Forces driving competition in the generics market in China, 2016

Figure 21: Drivers of buyer power in the generics market in China, 2016

Figure 22: Drivers of supplier power in the generics market in China, 2016

Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 25: Drivers of degree of rivalry in the generics market in China, 2016

Figure 26: India generics market value: $ billion, 2012-16

Figure 27: India generics market volume: % of total pharma volume, 2012-16

Figure 28: India generics market geography segmentation: % share, by value, 2016

Figure 29: India generics market value forecast: $ billion, 2016-21

Figure 30: India generics market volume forecast: % of total pharma volume, 2016-21

Figure 31: Forces driving competition in the generics market in India, 2016

Figure 32: Drivers of buyer power in the generics market in India, 2016

Figure 33: Drivers of supplier power in the generics market in India, 2016

Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2016

Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2016

Figure 36: Drivers of degree of rivalry in the generics market in India, 2016

Figure 37: Russia generics market value: $ billion, 2012-16

Figure 38: Russia generics market volume: % of total pharma volume, 2012-16

Figure 39: Russia generics market geography segmentation: % share, by value, 2016

Figure 40: Russia generics market value forecast: $ billion, 2016-21

Figure 41: Russia generics market volume forecast: % of total pharma volume, 2016-21

Figure 42: Forces driving competition in the generics market in Russia, 2016

Figure 43: Drivers of buyer power in the generics market in Russia, 2016

Figure 44: Drivers of supplier power in the generics market in Russia, 2016

Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2016

Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2016

Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2016

Figure 48: Sanofi SA: revenues & profitability

Figure 49: Sanofi SA: assets & liabilities

Figure 50: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 51: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

Figure 52: Mylan Inc.: revenues & profitability

Figure 53: Mylan Inc.: assets & liabilities

Figure 54: Aurobindo Pharma Limited: revenues & profitability

Figure 55: Aurobindo Pharma Limited: assets & liabilities

Figure 56: Cipla Limited: revenues & profitability

Figure 57: Cipla Limited: assets & liabilities

Figure 58: Lupin Limited: revenues & profitability

Figure 59: Lupin Limited: assets & liabilities

Figure 60: Sun Pharmaceutical Industries Ltd.: revenues & profitability

Figure 61: Sun Pharmaceutical Industries Ltd.: assets & liabilities

Figure 62: Abbott Laboratories: revenues & profitability

Figure 63: Abbott Laboratories: assets & liabilities

Figure 64: Krka, d. d., Novo mesto: revenues & profitability

Figure 65: Krka, d. d., Novo mesto: assets & liabilities

Figure 66: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 67: Teva Pharmaceutical Industries Limited: assets & liabilities

List of Tables

Table 1: BRIC generics industry, revenue($bn), 2012-21

Table 2: BRIC generics industry, revenue($bn), 2012-16

Table 3: BRIC generics industry, revenue($bn), 2016-21

Table 4: Brazil generics market value: $ billion, 2012-16

Table 5: Brazil generics market volume: % of total pharma volume, 2012-16

Table 6: Brazil generics market geography segmentation: $ billion, 2016

Table 7: Brazil generics market value forecast: $ billion, 2016-21

Table 8: Brazil generics market volume forecast: % of total pharma volume, 2016-21

Table 9: Brazil size of population (million), 2012-16

Table 10: Brazil gdp (constant 2005 prices, $ billion), 2012-16

Table 11: Brazil gdp (current prices, $ billion), 2012-16

Table 12: Brazil inflation, 2012-16

Table 13: Brazil consumer price index (absolute), 2012-16

Table 14: Brazil exchange rate, 2012-16

Table 15: China generics market value: $ billion, 2012-16

Table 16: China generics market volume: % of total pharma volume, 2012-16

Table 17: China generics market geography segmentation: $ billion, 2016

Table 18: China generics market value forecast: $ billion, 2016-21

Table 19: China generics market volume forecast: % of total pharma volume, 2016-21

Table 20: China size of population (million), 2012-16

Table 21: China gdp (constant 2005 prices, $ billion), 2012-16

Table 22: China gdp (current prices, $ billion), 2012-16

Table 23: China inflation, 2012-16

Table 24: China consumer price index (absolute), 2012-16

Table 25: China exchange rate, 2012-16

Table 26: India generics market value: $ billion, 2012-16

Table 27: India generics market volume: % of total pharma volume, 2012-16

Table 28: India generics market geography segmentation: $ billion, 2016

Table 29: India generics market value forecast: $ billion, 2016-21

Table 30: India generics market volume forecast: % of total pharma volume, 2016-21

Table 31: India size of population (million), 2012-16

Table 32: India gdp (constant 2005 prices, $ billion), 2012-16

Table 33: India gdp (current prices, $ billion), 2012-16

Table 34: India inflation, 2012-16

Table 35: India consumer price index (absolute), 2012-16

Table 36: India exchange rate, 2012-16

Table 37: Russia generics market value: $ billion, 2012-16

Table 38: Russia generics market volume: % of total pharma volume, 2012-16

Table 39: Russia generics market geography segmentation: $ billion, 2016

Table 40: Russia generics market value forecast: $ billion, 2016-21

Table 41: Russia generics market volume forecast: % of total pharma volume, 2016-21

Table 42: Russia size of population (million), 2012-16

Table 43: Russia gdp (constant 2005 prices, $ billion), 2012-16

Table 44: Russia gdp (current prices, $ billion), 2012-16

Table 45: Russia inflation, 2012-16

Table 46: Russia consumer price index (absolute), 2012-16

Table 47: Russia exchange rate, 2012-16

Table 48: O Ache Laboratorios Farmaceuticos S.A.: key facts

Table 49: EMS Sigma Pharma: key facts

Table 50: Eurofarma Laboratorios S.A.: key facts

Table 51: Sanofi SA: key facts

Table 52: Sanofi SA: key financials ($)

Table 53: Sanofi SA: key financials (EUR)

Table 54: Sanofi SA: key financial ratios

Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)

Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 59: Mylan Inc.: key facts

Table 60: Mylan Inc.: key financials ($)

Table 61: Mylan Inc.: key financial ratios

Table 62: Sandoz International GmbH: key facts

Table 63: Aurobindo Pharma Limited: key facts

Table 64: Aurobindo Pharma Limited: key financials ($)

Table 65: Aurobindo Pharma Limited: key financials (Rs.)

Table 66: Aurobindo Pharma Limited: key financial ratios

Table 67: Cipla Limited: key facts

Table 68: Cipla Limited: key financials ($)

Table 69: Cipla Limited: key financials (Rs.)

Table 70: Cipla Limited: key financial ratios

Table 71: Lupin Limited: key facts

Table 72: Lupin Limited: key financials ($)

Table 73: Lupin Limited: key financials (Rs.)

Table 74: Lupin Limited: key financial ratios

Table 75: Sun Pharmaceutical Industries Ltd.: key facts

Table 76: Sun Pharmaceutical Industries Ltd.: key financials ($)

Table 77: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)

Table 78: Sun Pharmaceutical Industries Ltd.: key financial ratios

Table 79: Abbott Laboratories: key facts

Table 80: Abbott Laboratories: key financials ($)

Table 81: Abbott Laboratories: key financial ratios

Table 82: Krka, d. d., Novo mesto: key facts

Table 83: Krka, d. d., Novo mesto: key financials ($)

Table 84: Krka, d. d., Novo mesto: key financials (EUR)

Table 85: Krka, d. d., Novo mesto: key financial ratios

Table 86: Teva Pharmaceutical Industries Limited: key facts

Table 87: Teva Pharmaceutical Industries Limited: key financials ($)

Table 88: Teva Pharmaceutical Industries Limited: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person